Pharmacokinetics and Pharmacodynamics Practice Questions

Q: What are the purposes of using epinephrine in conjunction with local anesthetics?

All of the options. ***All of the options*** - Epinephrine is a **vasoconstrictor** that produces all three of the listed benefits when combined with local anesthetics. - The **vasoconstrictive effect** reduces blood flow at the injection site, which simultaneously achieves multiple therapeutic purposes. - All three mechanisms work together through a single pharmacological action: **local vasoconstriction**. **1. Prolongs the duration of anesthesia:** - Vasoconstriction reduces blood flow to the area, delaying the washout of the local anesthetic from the nerve site. - This maintains a higher local concentration of anesthetic for a longer period, extending the duration of nerve block. - Duration can be increased by 50-100% depending on the site and anesthetic used. **2. Decreases systemic absorption:** - By constricting local blood vessels, epinephrine slows the rate at which the local anesthetic enters the systemic circulation. - This reduces peak plasma concentrations, **lowering the risk of systemic toxicity** (CNS and cardiac effects). - Allows use of higher total doses of local anesthetic when needed. **3. Reduces bleeding:** - The vasoconstrictive effect directly narrows small blood vessels in the surgical field. - This **reduces capillary bleeding**, improving surgical visibility and decreasing blood loss during procedures. - Particularly useful in highly vascular areas like the oral cavity and scalp.

Q: A drug has a therapeutic index of 5 and an ED50 of 2 mg. What is the LD50 of the drug?

10 mg. ***10 mg*** - The **therapeutic index (TI)** is calculated as **LD50 / ED50**. - Given a TI of 5 and an ED50 of 2 mg, the LD50 = TI × ED50 = 5 × 2 mg = **10 mg**. - This is the correct application of the therapeutic index formula. *15 mg* - This value would imply a therapeutic index of 7.5 (15 mg / 2 mg), which is incorrect based on the given information. - Does not align with the definition and calculation of the therapeutic index. *8 mg* - This value would result in a therapeutic index of 4 (8 mg / 2 mg), not the given TI of 5. - Represents an incorrect application of the therapeutic index formula. *12 mg* - This value would yield a therapeutic index of 6 (12 mg / 2 mg), differing from the provided TI of 5. - Does not correctly reflect the relationship between ED50, LD50, and the therapeutic index.

Q: A new drug shows that its therapeutic dose-response curve and toxic dose-response curve are closely positioned on the dose axis. What can be inferred about its therapeutic index and safety profile?

Lower therapeutic index, increased risk of toxicity. ***Lower therapeutic index, increased risk of toxicity*** - When the **therapeutic and toxic dose-response curves are closely positioned**, there is a narrow margin between the dose that produces therapeutic effects and the dose that causes toxicity - This narrow separation indicates a **low therapeutic index (TI = TD50/ED50)**, where TD50 (toxic dose) and ED50 (effective dose) are close in value - Clinically, this means **increased risk of toxicity** as small dose increases or patient variability can easily shift from therapeutic to toxic range - Examples include drugs like **digoxin, warfarin, and aminoglycosides** which require careful monitoring *Higher therapeutic index, increased safety* - This would be true if the toxic dose-response curve was **far separated** from the therapeutic curve on the dose axis - Close positioning of curves indicates **low, not high** therapeutic index - Higher therapeutic index drugs have a wide safety margin (e.g., penicillins, most NSAIDs) *Lower therapeutic index, unchanged efficacy* - While **lower therapeutic index** is correct, "unchanged efficacy" is not a relevant inference from curve positioning - **Efficacy** refers to the maximal effect (Emax), represented by the plateau height of the dose-response curve, not its position on the dose axis - Therapeutic index and efficacy are independent parameters *Higher therapeutic index, unchanged potency* - Close positioning of therapeutic and toxic curves indicates **lower, not higher** therapeutic index - **Potency** (dose required for effect, reflected by ED50 position) is independent of therapeutic index - A drug can be highly potent but have a low therapeutic index if toxic effects occur at doses close to therapeutic doses

Q: A patient requires immediate relief from an acute asthma attack. Which route of administration would provide the fastest effect?

Inhalation. ***Inhalation*** - **Inhalation** delivers medication directly to the **airways**, the site of action for asthma, allowing for rapid absorption and immediate local bronchodilation. - This route provides **targeted drug delivery** to bronchial smooth muscle, achieving therapeutic effect within **1-5 minutes** for acute asthma relief. - Bypasses first-pass metabolism and requires **lower doses** due to direct delivery to the target organ. - **First-line treatment** for acute asthma attacks in clinical practice. *Oral* - **Oral administration** involves absorption from the gastrointestinal tract, which is a slower process, with onset typically taking **30-60 minutes**. - Medications taken orally undergo **first-pass metabolism** in the liver, reducing bioavailability and delaying therapeutic effect. - Not suitable for **acute** asthma management due to delayed onset. *Subcutaneous* - **Subcutaneous injections** are absorbed more slowly than intravenous or inhaled routes, with onset in **15-30 minutes**. - The drug must diffuse from subcutaneous tissue into the bloodstream before reaching the lungs. - May be used for severe asthma (e.g., subcutaneous epinephrine) but **not preferred** over inhalation for typical acute attacks. *Intravenous* - While **intravenous administration** provides immediate systemic delivery with rapid onset, it is **not the first choice** for acute asthma. - Reserved for **severe, life-threatening asthma** unresponsive to inhaled therapy. - Requires IV access, medical supervision, and carries higher risk of systemic side effects. - For acute asthma relief, **inhaled bronchodilators act faster at the target site** despite IV having faster systemic absorption.

Q: A patient with a severe infection is given a drug with a half-life of 8 hours. How long will it take for the drug's concentration to decrease to 25% of its original value?

16 hours. ***16 hours (Correct)*** - After one **half-life** (8 hours), the drug concentration will be 50% of the original value. - After two half-lives (8 hours + 8 hours = **16 hours**), the drug concentration will be 25% of the original value (50% of 50%). - This follows the exponential decay formula: remaining concentration = (1/2)^n, where n is the number of half-lives. *8 hours (Incorrect)* - This represents only one half-life, at which point the drug's concentration would be reduced to 50%, not 25%, of its original value. - The question asks for the time to reach 25% concentration, which requires an additional half-life. *24 hours (Incorrect)* - This duration represents three half-lives (8 hours × 3). - After three half-lives, the drug concentration would be 12.5% of its original value (50% → 25% → 12.5%). *32 hours (Incorrect)* - This duration represents four half-lives (8 hours × 4). - After four half-lives, the drug concentration would be 6.25% of its original value (12.5% → 6.25%).

Q: Comparing cisplatin and carboplatin, which factor primarily accounts for the difference in nephrotoxicity between these two chemotherapeutic agents?

Different rates of renal clearance. ***Different rates of renal clearance*** - **Cisplatin** is largely cleared by **glomerular filtration** and **tubular secretion**, leading to higher concentrations in the renal tubules and increased nephrotoxicity. - **Carboplatin** is primarily cleared by **glomerular filtration** without significant tubular secretion, resulting in lower renal exposure and reduced nephrotoxicity. *Variability in DNA adduct formation* - While both drugs form DNA adducts to exert their therapeutic effect, the specific differences in adduct formation do not primarily explain their differential nephrotoxicity. - The mechanism of nephrotoxicity is more related to the drugs' delivery and concentration in renal cells rather than the inherent nature of their DNA-damaging activity. *Difference in protein binding* - Both cisplatin and carboplatin bind to plasma proteins, but this factor alone does not account for the significant difference in their nephrotoxic profiles. - Protein binding can influence drug distribution and elimination, but the **intrinsic renal handling** mechanisms are more critical for specific organ toxicity. *Dose-dependent cellular uptake* - Both drugs exhibit dose-dependent cellular uptake in target cancer cells, which is crucial for efficacy. - However, the **differential nephrotoxicity** is more closely tied to their **pharmacokinetics** within the kidney itself (e.g., clearance rates) rather than just general cellular uptake.

Q: In a drug exhibiting first-order kinetics, how would an increase in dose affect the time required to reach the steady-state concentration?

It would not change. ***It would not change*** - For drugs following **first-order kinetics**, the time required to reach steady-state concentration is determined solely by the **half-life (t½)** of the drug, which is independent of the dose. - Steady-state is generally achieved after approximately **4 to 5 half-lives**, regardless of the administered dose size, provided the dosing interval remains constant. *It would decrease* - An increase in dose does not shorten the time to reach steady state for a first-order drug, as the **elimination rate** is proportional to the plasma concentration. - The drug still needs to undergo the same number of half-lives to accumulate to a steady level. *It would increase* - Increasing the dose does not prolong the time to reach steady state for a drug exhibiting first-order kinetics. - The **kinetics of elimination** remain proportional to the amount of drug in the body, meaning a larger dose will be eliminated proportionally faster, maintaining the same half-life. *It would double* - The time to reach steady state is a function of the drug's elimination half-life, not the magnitude of the dose. - Doubling the dose will **double the steady-state concentration**, but not the time it takes to achieve that concentration.

Q: The graph below shows dose-response curves for three drugs A, B, and C. Which of the following drugs has the highest potency?

Drug A. ***Drug A*** - Potency is inversely related to the **concentration required to produce an effect (EC50)**. A lower EC50 indicates higher potency. - Drug A achieves its half-maximal effect (indicated by the dashed line) at approximately **0.01 concentration**, which is the lowest among all three drugs. *Drug B* - Drug B reaches its half-maximal effect at a concentration of approximately **1**, which is significantly higher than Drug A. - This indicates that a larger dose of Drug B is needed to achieve the same effect as Drug A, making it less potent than A. *Drug C* - Drug C requires the highest concentration, approximately **100**, to achieve its half-maximal effect. - This signifies that Drug C is the least potent among the three drugs, as it demands a much larger dose for an equivalent effect compared to A and B. *Both Drug A & B* - While Drug A is highly potent, Drug B is less potent as it requires a higher concentration to elicit its effect. - Therefore, it is incorrect to state that both drugs A and B have the highest potency.

Question 1

What are the purposes of using epinephrine in conjunction with local anesthetics?

Accepted Answer

All of the options

Answer

To prolong the duration of anesthesia

Answer

To decrease systemic absorption

Answer

To reduce bleeding

Question 2

A drug has a therapeutic index of 5 and an ED50 of 2 mg. What is the LD50 of the drug?

Accepted Answer

10 mg

Answer

15 mg

Answer

8 mg

Answer

12 mg

Question 3

A new drug shows that its therapeutic dose-response curve and toxic dose-response curve are closely positioned on the dose axis. What can be inferred about its therapeutic index and safety profile?

Accepted Answer

Lower therapeutic index, increased risk of toxicity

Answer

Higher therapeutic index, increased safety

Answer

Lower therapeutic index, unchanged efficacy

Answer

Higher therapeutic index, unchanged potency

Question 4

When comparing oral and intravenous routes of administration, which statement best describes the difference in bioavailability?

Accepted Answer

Oral has lower bioavailability due to first-pass metabolism.

Answer

Oral has lower bioavailability due to prolonged absorption.

Answer

Intravenous has higher bioavailability due to rapid distribution.

Answer

Intravenous has higher bioavailability due to increased absorption.

Question 5

A patient requires immediate relief from an acute asthma attack. Which route of administration would provide the fastest effect?

Accepted Answer

Inhalation

Answer

Oral

Answer

Subcutaneous

Answer

Intravenous

Question 6

A patient with a severe infection is given a drug with a half-life of 8 hours. How long will it take for the drug's concentration to decrease to 25% of its original value?

Accepted Answer

16 hours

Answer

8 hours

Answer

24 hours

Answer

32 hours

Question 7

Comparing cisplatin and carboplatin, which factor primarily accounts for the difference in nephrotoxicity between these two chemotherapeutic agents?

Accepted Answer

Different rates of renal clearance

Answer

Variability in DNA adduct formation

Answer

Difference in protein binding

Answer

Dose-dependent cellular uptake

Question 8

Which of the following statements is most accurate regarding why fentanyl is preferred over morphine for acute pain management in emergency settings?

Accepted Answer

Fentanyl is more suitable for acute pain management due to its rapid onset.

Answer

Morphine has a longer duration of action than fentanyl.

Answer

Fentanyl has lower lipid solubility than morphine.

Answer

Morphine is completely ineffective for acute pain management.

Question 9

In a drug exhibiting first-order kinetics, how would an increase in dose affect the time required to reach the steady-state concentration?

Accepted Answer

It would not change

Answer

It would decrease

Answer

It would increase

Answer

It would double

Question 10

The graph below shows dose-response curves for three drugs A, B, and C. Which of the following drugs has the highest potency?

Accepted Answer

Drug A

Answer

Drug B

Answer

Drug C

Answer

Both Drug A & B

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?